IL6 and neoplasm: These results are in line with a number of studies demonstrating increased inflammation and autoimmune activities in patients receiving ICI therapy.48 Importantly, we show that therapeutic efficacy of anti-CTLA-4 is significantly improved by the coadministration of neutralizing antibodies against IL-6 in tumor-bearing mice.